Overview

* NeuroPace ( NPCE ) Q3 revenue of $27.4 mln grows 30%, beating analyst expectations

* Gross margin improved to 77.4% due to product mix and efficiencies

Outlook

* NeuroPace ( NPCE ) raises 2025 revenue guidance to $97 mln-$98 mln

* Company increases 2025 gross margin guidance to 76%-77%

* NeuroPace ( NPCE ) plans NAUTILUS PMA Supplement submission by year-end 2025

Result Drivers

* RNS SYSTEM SALES - Co reports 31% growth in RNS System revenue, driving overall revenue increase

* GROSS MARGIN IMPROVEMENT - Favorable product mix and manufacturing efficiencies boosted gross margin to 77.4%

* OPERATIONAL MOMENTUM - Submission of Seizure ID™ to FDA and progress on NAUTILUS study contributed to strategic momentum

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $27.35 $24.63

Revenue mln mln (8

Analysts

)

Q3 EPS -$0.11

Q3 Net -$3.49

Income mln

Q3 Gross $21.16

Profit mln

Q3 -$2.60

Income mln

from

Operatio

ns

Q3 $23.76

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Neuropace Inc ( NPCE ) is $18.00, about 47.8% above its November 3 closing price of $9.40

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)